Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The shares closed down nearly 12% after CVS Health's revelation and Lilly's announcement that, despite a 45% surge in first-quarter revenues driven by Zepbound (tirzepatide) and diabetes ...

Meanwhile, the Danish drugmaker was also bolstered by the decision by pharmacy benefit manager (PBM) CVS Health to remove Zepbound but retain Wegovy on its formulary of reimbursed medicines.

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

However, CVS disagrees. In May, the company filed a federal lawsuit, calling Act 624 unconstitutional, and claiming it unfairly targets out-of-state operators while exempting local interests.

Experts outline who qualifies for weight-loss medications, highlighting benefits beyond obesity treatment while noting potential side effects and the need for lifestyle changes.